Urine and blood markers for men with advanced prostate cancer on hormone therapy
Part of Cancer clinical trials.
This study looks at how well urine and blood tests can monitor treatment response in men with prostate cancer that has spread. It includes both men who are starting a new hormone therapy and those who have already been on one but are seeing their cancer progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- Your prostate cancer must have spread to other parts of the body (like bones, lymph nodes, or other organs) – not just the prostate area.
- If you are starting a new hormone treatment (like darolutamide) for the first time, you must not have had it for more than 3 months already.
- If you are already taking a newer hormone therapy (such as abiraterone, apalutamide, darolutamide, or enzalutamide) and your cancer has started to grow, you may be eligible.
- You must be willing to stay on certain standard hormone therapy medications throughout the study.
- You must provide urine and blood samples for analysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
This trial tests a new way to predict how well hormone therapy combined with newer drugs works for men with prostate cancer that has spread. It uses advanced tissue analysis to help tailor treatment.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This study looks for urine markers (proteins and metabolites) that may help predict how prostate cancer patients respond to treatment and what their outcomes are. You may be asked to give a urine sample and allow use of your medical and treatment details for analysis (results are not shared with you).
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.